Related Experiment Video
Updated: Jul 7, 2026

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
Xue-Jie-San alleviates Crohn's disease through suppressing endothelial cell pyroptosis via the TLR4/NF-κB/NLRP3
Ying Gao1, Yi-Qian Zhu1, Ke-Hua Liu1
1Department of Colorectal Surgery, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, 215000, China.
Ethnopharmacological Relevance:
Chinese herbs with the effects of promoting blood circulation and removing stasis play a vital role in CD treatment. However, research on the mechanisms by which they work is rare. Xue-Jie-San (XJS) has exhibited excellent efficacy in ameliorating CD, but how it works is unclearly known.
Aim Of The Study:
The present study attempted to investigate whether XJS treating CD by restoring the function of the endothelial barrier through hindering NLRP3 inflammasome-mediated pyroptosis and uncover the potential mechanisms of blood-activating and stasis-removing herbs in treating CD.
Materials And Methods:
Lipopolysaccharide-stimulated human umbilical vein endothelial cells and CD rats were subjected to XJS treatment. Colitis symptoms were recorded and histopathological damages were evaluated by hematoxylin-eosin staining. The function of vascular endothelial barrier was assessed via detecting vascular permeability and the levels of tight junction proteins through immunofluorescence staining and Western blot. Enzyme-linked immunosorbent assay was utilized to detect IL-1β and IL-18 concentrations. Endothelial cell pyroptosis and NLRP3 inflammasome activation mediated by TLR4 signaling were detected through multiple detection techniques.
Results:
XJS treatment mitigated the symptoms and histopathological damages of CD-like colitis. The function of vascular endothelial barrier was restored by XJS via reducing its permeability and upregulating the expressions of tight junction protein ZO-1 and OCLN. Pyroptosis-mediated inflammatory response was suppressed as reflected by decreased IL-1β and IL-18 concentrations. Meanwhile, the upregulated expressions of pyroptosis executor GSDMD and GSDMD-N were also precluded by XJS. Additionally, XJS administration inhibited the NLRP3 inflammasome activation via diminishing the expressions of NLRP3, ASC, pro-caspase1 and caspase1. The canonical upstream TLR4/MyD88/NF-κB signal that transcriptionally regulated NLRP3 expression was also blocked. In vitro, overexpressing TLR4 abolished the effect of XJS on inhibiting endothelial cell pyroptosis.
Conclusion:
XJS might ameliorate CD-like colitis via restoring vascular endothelial barrier through regulating TLR4 signaling and debilitating the activity of NLRP3 inflammasome. This work disclosed a potential mechanism of blood-activating and stasis-removing herbs in treating CD.
More Related Videos
06:12Author Spotlight: THP-1 Macrophage Response to LPS/ATP — Unveiling the Pyroptosis, Apoptosis, and Necroptosis Spectrum
Published on: May 3, 2024
09:44Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease III: Crohn's Disease